PPARA and central nervous system cancer: Chiglitazar, an agent currently used for treating type II diabetes has been identifies as a PPAR agonist [17], significantly induces apoptosis by enhancing the expression of PPARα in HepG2 cells [18] and triggers apoptosis in tumor cells in glioma [19] and mantle cell lymphoma (MCL) [20].